Citigroup’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-17,500
| Closed | -$299K | – | 6313 |
|
|
2025
Q2 | $299K | Hold |
17,500
| – | – | ﹤0.01% | 3878 |
|
|
2025
Q1 | $1.12M | Sell |
17,500
-2,500
| -13% | -$263K | ﹤0.01% | 3166 |
|
|
2024
Q4 | $2.43M | Sell |
20,000
-3,900
| -16% | -$478K | ﹤0.01% | 2649 |
|
|
2024
Q3 | $2.98M | Sell |
23,900
-2,800
| -10% | -$387K | ﹤0.01% | 2312 |
|
|
2024
Q2 | $4.22M | Buy |
26,700
+25,000
| +1,471% | +$3.21M | ﹤0.01% | 1756 |
|
|
2024
Q1 | $220K | Sell |
1,700
-13,300
| -89% | -$1.63M | ﹤0.01% | 3974 |
|
|
2023
Q4 | $1.45M | Sell |
15,000
-5,000
| -25% | -$480K | ﹤0.01% | 2522 |
|
|
2023
Q3 | $2.42M | Buy |
+20,000
| New | +$2.26M | ﹤0.01% | 1866 |
|
|
2023
Q2 | – | Sell |
-21,400
| Closed | -$2.95M | – | 5720 |
|
|
2023
Q1 | $2.95M | Buy |
21,400
+21,300
| +21,300% | +$2.76M | ﹤0.01% | 1771 |
|
|
2022
Q4 | $13K | Sell |
100
-58,600
| -100% | -$6.79M | ﹤0.01% | 4753 |
|
|
2022
Q3 | $6.49M | Buy |
+58,700
| New | +$5.92M | ﹤0.01% | 1392 |
|
|
2021
Q1 | – | Sell |
-43,900
| Closed | -$7.49M | – | 7292 |
|
|
2020
Q4 | $7.49M | Sell |
43,900
-9,100
| -17% | -$1.35M | ﹤0.01% | 1794 |
|
|
2020
Q3 | $7.44M | Buy |
53,000
+5,100
| +11% | +$775K | ﹤0.01% | 1612 |
|
|
2020
Q2 | $7.68M | Buy |
47,900
+6,300
| +15% | +$857K | 0.01% | 1521 |
|
|
2020
Q1 | $4.07M | Sell |
41,600
-81,600
| -66% | -$9.33M | ﹤0.01% | 1848 |
|
|
2019
Q4 | $15.9M | Buy |
123,200
+57,800
| +88% | +$5.83M | 0.01% | 1114 |
|
|
2019
Q3 | $4.93M | Sell |
65,400
-378,100
| -85% | -$44.7M | ﹤0.01% | 1956 |
|
|
2019
Q2 | $67.4M | Buy |
443,500
+369,100
| +496% | +$44.9M | 0.05% | 337 |
|
|
2019
Q1 | $8.87M | Sell |
74,400
-1,100
| -1% | -$141K | 0.01% | 1349 |
|
|
2018
Q4 | $8.24M | Buy |
75,500
+20,000
| +36% | +$2.5M | 0.01% | 1410 |
|
|
2018
Q3 | $8.96M | Sell |
55,500
-600
| -1% | -$82K | 0.01% | 1364 |
|
|
2018
Q2 | $7.42M | Buy |
56,100
+22,500
| +67% | +$2.12M | 0.01% | 1497 |
|
|
2018
Q1 | $2.49M | Sell |
33,600
-7,900
| -19% | -$527K | ﹤0.01% | 2412 |
|
|
2017
Q4 | $2.31M | Sell |
41,500
-20,900
| -33% | -$1.11M | ﹤0.01% | 2527 |
|
|
2017
Q3 | $2.83M | Buy |
62,400
+23,400
| +60% | +$935K | ﹤0.01% | 2298 |
|
|
2017
Q2 | $1.31M | Buy |
39,000
+12,200
| +46% | +$397K | ﹤0.01% | 3026 |
|
|
2017
Q1 | $793K | Sell |
26,800
-9,800
| -27% | -$303K | ﹤0.01% | 3455 |
|
|
2016
Q4 | $1M | Sell |
36,600
-34,900
| -49% | -$1.4M | ﹤0.01% | 3691 |
|
|
2016
Q3 | $4.39M | Buy |
71,500
+9,100
| +15% | +$275K | ﹤0.01% | 1779 |
|
|
2016
Q2 | $1.19M | Sell |
62,400
-17,300
| -22% | -$320K | ﹤0.01% | 2784 |
|
|
2016
Q1 | $1.56M | Sell |
79,700
-29,100
| -27% | -$508K | ﹤0.01% | 2811 |
|
|
2015
Q4 | $4.2M | Buy |
108,800
+50,900
| +88% | +$1.65M | ﹤0.01% | 1849 |
|
|
2015
Q3 | $1.86M | Sell |
57,900
-4,200
| -7% | -$143K | ﹤0.01% | 2516 |
|
|
2015
Q2 | $1.89M | Buy |
62,100
+14,700
| +31% | +$301K | ﹤0.01% | 2572 |
|
|
2015
Q1 | $629K | Buy |
47,400
+32,700
| +222% | +$436K | ﹤0.01% | 3528 |
|
|
2014
Q4 | $213K | Buy |
+14,700
| New | +$249K | ﹤0.01% | 4637 |
|
Other funds holding SRPT
VPM
VCM
RCM
EAM
Citigroup's SRPT Position: Q1 2026 in Review
Citigroup increased its Sarepta Therapeutics (SRPT) stake by 0.13% in Q1 2026, buying an estimated $28.5K and bringing the position to 1,147,648 shares worth $25M. The position accounts for 0.01% of the portfolio, ranked #955.
Citigroup first reported a position in SRPT in Q2 2013 and has held it in 52 quarters since. The position peaked at $34.2M in Q2 2019. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.
- Citigroup held 1,147,648 shares of Sarepta Therapeutics worth $25M as of Q1 2026.
- Citigroup bought 1,473 Sarepta Therapeutics shares in Q1 2026, an estimated $28.5K.
- Sarepta Therapeutics made up 0.01% of Citigroup's portfolio in Q1 2026, its #955 holding.
- Citigroup first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 52 quarters since.
- Citigroup's Sarepta Therapeutics position peaked at $34.2M in Q2 2019.
- 339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.